• Nenhum resultado encontrado

BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.

N/A
N/A
Protected

Academic year: 2017

Share "BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia."

Copied!
4
0
0

Texto

Loading

Imagem

Figure 1. BCR-ABL downregulates PTEN expression. A) Left panel: evaluation of PTEN levels of expression in BCR-ABL-pcDNA3.1 transfected NIH3T3
Figure 2. PTEN in CML blast crisis. A) PTEN protein levels in CML blast crisis. Jurkat cell line was used as a PTEN null cell line

Referências

Documentos relacionados

the vast majority of CML patients, as well as in 30% of adult acute lymphoblastic leukemia (ALL) and 20% of childhood chromosome Ph positive ALL, the breakpoint in the BCR gene

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase – the importance of a major molecular response1. Medical

Extraordinary scientific progress made in the field of chronic myeloid leukemia (CML) led to the development of orally available tyrosine kinase inhibitors (TKIs), dramatically

The identification of BCR-ABL expression as the defining leu- kemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors (TKIs)

Multiple BCR-ABL kinase domain mutations confer polyclonal resis- tance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid

Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Molecu-

Evaluation of the expression of the tumor suppressor gene PTEN, proto-oncogene c-kit, matrilysin (MMP-7), Connexins 32 and 43 and E- caderinas/cateninas complex in mast